产品销售情况 - 公司第二季度Qelbree处方量为184,342个，同比增长26%[151] - 第二季度Qelbree、GOCOVRI和Oxtellar XR的销售额分别同比增长92%、10%和24%[160] - 第二季度Trokendi XR的销售额同比下降12%,主要受到专利到期后的仿制药竞争影响[160] 新药研发进展 - 公司已于8月重新向FDA提交了SPN-830(阿朴吗啡持续输注装置)新药申请[152] - SPN-820正在进行II期临床试验,评估其在治疗难治性抑郁症中的疗效和安全性,预计2025年上半年公布试验结果[154] - SPN-817正在进行II期临床试验,评估其在治疗难治性局灶性癫痫中的疗效,预计2024年下半年公布试验结果[156] - 公司计划于2024年启动SPN-443(新型ADHD/CNS刺激剂)的I期单剂量临床试验,评估其安全性和耐受性[158] 财务情况 - 第二季度公司总收入为1.683亿美元,同比增长24%[160] - 公司授权和许可收入同比下降20%,主要是由于2023年同期有一次性收入[160] - 公司现金及现金等价物、有价证券余额为3.472亿美元，较2023年12月31日增加7,570万美元(28%)[181] - 经营活动产生的现金流量为7,402.5万美元，较2023年同期增加4,377.3万美元[186] - 投资活动使用的现金流量为1.002亿美元，较2023年同期减少4.003亿美元[187] - 融资活动产生的现金流量为322.8万美元，较2023年同期增加4.020亿美元[188] 应收应付情况 - 应收产品退货余额从2023年6月30日的5,128.8万美元增加至2024年6月30日的5,853.7万美元[169] - 应付产品返利余额从2023年6月30日的9,753.8万美元增加至2024年6月30日的1.166亿美元[170] - 产品退货计提从2023年同期的1,166.8万美元减少至2024年同期的671.9万美元[171] - 产品返利计提从2023年同期的2.114亿美元减少至2024年同期的1.990亿美元[172] 资金管理 - 公司现金和现金等价物、有价证券和长期有价证券总额为3.472亿美元[191] - 公司与UBS签有信用额度协议,可获得最高1.5亿美元的循环信贷额度,截至2024年6月30日尚未使用[191] - 公司的信用额度以公司的有价证券组合作为抵押,如果抵押品价值下跌导致低于要求,公司可能需要及时补充抵押品[192] - 公司的现金及现金等价物主要为银行存款和三个月内到期的高流动性金融工具[193] - 公司的有价证券主要包括美国国债、银行存单、政府机构债券以及公司和市政债券,到期期限通常为1-4年[193] - 公司目前未对外汇风险进行套期保值[194,195] - 公司认为通胀和价格变化在2023年和2024年上半年对合并经营业绩没有重大影响[196]

Exhibit 99.1 Supernus Announces Second Quarter 2024 Financial Results ® • Net sales of Qelbree increased 92% in the second quarter of 2024, compared to the same period in 2023. ◦ $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. • Net sales of GOCOVRI increased 10% in the second quarter of 2024, compared to the same period in 2023. ® ◦ $31.7 million and $58.3 million of net sales in the second quarter and first six months of 2024, respectively. • ...

Net sales of Qelbree® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. Net sales of GOCOVRI® increased 10% in the second quarter of 2024, compared to the same period in 2023. $31.7 million and $58.3 million of net sales in the second quarter and first six months of 2024, respectively. Total revenues were $168.3 million in the second quarter of 2024, an increase of ...

ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD). Supernus believes it has addressed the U.S. Food and Drug Administrat ...

ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD). Supernus believes it has addressed the U.S. Food and Drug Administrat ...

ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to pre ...

SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced data from the planned interim analysis of the exploratory open-label Phase 2a clinic ...

 SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced data from the planned interim analysis of the exploratory open-label Phase 2a clini ...

NEW YORK, May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Supernus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action] On April 8, ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Stacy Ku - TD Cowen Jack Padovano - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-on ...